GLB-001

N/A

Report date: 2024/04/17 09:45:44
NME

Base Information

Drug NameGLB-001
Drug Alias NameGLB-C183-A-2GLB-001
ClassificationSmall molecules > Molecular Glue
Mechanisms of ActionCasein kinase I isoform alpha degraders
TargetsCasein kinase I isoform alpha
Therapy Area/IndicationsPrimary MyelofibrosisMyelodysplastic SyndromesThrombocythemia, Essential +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesGluBio Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesGluBio Therapeutics IncHangzhou GluBio Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsPrimary MyelofibrosisMyelodysplastic SyndromesThrombocythemia, Essential +[6] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A